Cellix has launched the Vena4Y and Vena4Y2 branching microchannel biochips for thrombosis and atherosclerosis studies.
Cellix's microfluidic-based biochips enables drug discovery using biochip designs that mimic human capillaries.
The biochips allow for the precise control of microlitre volumes of biochemical samples and reagents.
These latest biochip designs integrate flow-based cell-adhesion assays with branching microchannels, enabling researchers to mimic branching microvessels for studying thrombosis and atherosclerosis.
Vena4Y and the Vena4Y2 contain four parallel enclosed microcapillaries for continuous flow-cell-based assays: cell-receptor ligand rolling, binding/adhesion assays under shear flow.
Each microcapillary may be coated with a different adhesion molecule.
The biochips are suitable for the study of thrombosis applications: platelet adhesion, aggregation and thrombi formation in a robust in vitro setting that mimics branching microvessels in vivo.
Cellix's biochips enable researchers to mimic in vivo disease microenvironments, allowing detailed dissection of disease processes at the cellular level where shear stress or continuous flow parameters are known to affect physiologic events.
